A Promising Drug Target and Biomarker: CNPY3 (CTG4A) (G10695)

Target Name: CNPY3

NCBI ID: G10695

CNPY3

A Promising Drug Target and Biomarker: CNPY3 (CTG4A)

CNPY3 (CTG4A), a nucleotide-binding oligomerization domain (NOD) G protein-coupled receptor (GPCR), has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and psychiatric disorders. Its unique structural features and subcellular localization in the cell membrane have made it an attractive target for small molecules, making it an exciting area of research.

CNPY3: Structure and Subcellular Localization

The CNPY3 protein is a 21-kDa GPCR that consists of an extracellular domain, a transmembrane region, and an intracellular domain (CNPY3-IT). The extracellular domain has a N-terminal region that contains a nucleotide-binding oligomerization domain (NOD), which is responsible for the protein's nucleotide binding and oligomerization. The NOD is composed of a nucleotide-binding oligomerization domain (NOD), a 灏?-sheet, and a C-terminal region.

The transmembrane region (TMR) is responsible for the protein's ability to interact with the cell membrane and for its subcellular localization. The TMR is composed of a transmembrane region (TM), a short cytoplasmic tail (CT), and a unique N-terminal region that contains a putative G protein-coupled receptor (GPCR) domain. The TM is involved in the formation of the protein's transmembrane domain and is responsible for its stability and interactions with other proteins.

The intracellular domain (CNPY3-IT) is responsible for the protein's intracellular signaling and interaction with other cellular components. The CNPY3-IT domain has a N-terminal region that is similar to the NOD, a 灏?-sheet, and a C-terminal region.

Function and Druggability

The CNPY3 protein is a GPCR that plays a role in various physiological processes, including cell signaling, cell division, and neurotransmission. It is involved in the regulation of cell proliferation, differentiation, and survival, and its dysfunction has been implicated in various diseases, including cancer, neurodegenerative disorders, and psychiatric disorders.

The CNPY3 protein is a potential drug target due to its unique structure and subcellular localization. Its NOD and TMR domains have been shown to interact with small molecules and have high affinity for various ligands, making them attractive targets for small molecules. Additionally, the CNPY3 protein is known to have a unique expression pattern, with high expression in the brain and low expression in the rest of the body. This makes it an attractive target for small molecules that can modulate its expression and activity in the brain.

Despite its potential as a drug target, the CNPY3 protein is still under investigation as a biomarker for various diseases, including cancer, neurodegenerative disorders, and psychiatric disorders. The lack of human studies and the need for further studies to confirm its potential as a drug target make it an exciting area of research.

Conclusion

In conclusion, CNPY3 (CTG4A) is a promising drug target and biomarker due to its unique structure and subcellular localization. Its NOD and TMR domains have high affinity for various ligands and its unique expression pattern in the brain makes it an attractive target for small molecules. Further studies are needed to confirm its potential as a drug target and to investigate its role as a biomarker for various diseases.

Protein Name: Canopy FGF Signaling Regulator 3

Functions: Toll-like receptor (TLR)-specific co-chaperone for HSP90B1. Required for proper TLR folding, except that of TLR3, and hence controls TLR exit from the endoplasmic reticulum. Consequently, required for both innate and adaptive immune responses (By similarity)

The "CNPY3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CNPY3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets